NeuroStar’s technology once again recognized as an effective non-drug treatment for patientsMALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics,...
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures...
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapyMALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE)...
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company,...
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the...
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the...
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint...
KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"),...
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
Conference Call and Webcast at 5:00pm ET on November 14, 2022, Following the Oral PresentationTHE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE...
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression PatientsBURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022...
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 YearsBURLINGTON, Mass. and JERUSALEM, Nov. 01,...
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental healthMALVERN, Pa., Oct. 31, 2022...